Posts tagged yrosine kinase inhibitor
Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant HighGrade Neuroendocrine Tumor of the Lung
Novel MRPL13-ALK and PPP1CB-ALK Double Fusion As a Potential Mechanism of Acquired Resistance to First-Line Osimertinib in EGFR-Mutant HighGrade Neuroendocrine Tumor of the Lung

To our knowledge, this is the first report to state that that EGFR L858R and ALK double fusion were found in a high-grade neuroendocrine tumor of the lung. The rare ALK double fusion may be the potential reason for osimertinib resistance. Serine/threonine-PPP1CB (PPP1CBALK) fusion has already been reported in individual cases in glioma of infancy and leiomyosarcoma, but none in lung cancer. MRPL13-ALK is a novel fusion, which has never been reported yet. READ ARTICLE

JTO Clinical and Research Reports DOI:10.1016/j.jtocrr.2020.100079

Authors: Yuyan Jiao, MM, Ming Liu, MM, Ningning Luo, MS, Hao Guo, PhD, Jianzhe Li, PhD

Read More
Case StudyKirk Smithosimertinib, EGFR, yrosine kinase inhibitor, NSCLC, ALK